$INBS Intelligent Bio Solutions Implements Strategic Reorganization Plan to Support Global Growth Initiatives
https://www.globenewswire.com/news-release/20...tives.html
NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"
, a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the implementation of a strategic and comprehensive reorganization and productivity plan to support the Company’s global growth initiatives.
As the Company approaches several growth initiatives globally, including planned entry into the U.S. market in 2025, management has made the strategic decision to transition its operating structure from a UK-based model to a global framework. The reorganization aims to leverage the strengths of INBS’ diverse, international team and provide an agile structure as INBS expands its geographical footprint. Amongst other initiatives, the Company will operationally break down its regions into silos, which will enable more efficient collaboration and innovation between each, ensuring that the Company’s resources effectively align with growth objectives. This operational improvement will increase efficiency and position INBS for sustained, long-term success in the global market.
Harry Simeonidis, President and CEO at INBS, commented, “This strategic realignment will refocus priorities to better serve our global markets, enhancing productivity and creating synergies across our teams. The new functional structure will streamline operations, optimizing our ability to deliver our innovative, non-invasive medical technologies across the globe.”
INBS’ first-of-its-kind solution uses fingerprint sweat to provide a quick, hygienic, and easy-to-use method for drug testing, delivering results in just minutes. This unique approach tests for common drugs of abuse, including cocaine, cannabis, methamphetamine, and opiates.
https://www.globenewswire.com/news-release/20...tives.html
NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"
, a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the implementation of a strategic and comprehensive reorganization and productivity plan to support the Company’s global growth initiatives. As the Company approaches several growth initiatives globally, including planned entry into the U.S. market in 2025, management has made the strategic decision to transition its operating structure from a UK-based model to a global framework. The reorganization aims to leverage the strengths of INBS’ diverse, international team and provide an agile structure as INBS expands its geographical footprint. Amongst other initiatives, the Company will operationally break down its regions into silos, which will enable more efficient collaboration and innovation between each, ensuring that the Company’s resources effectively align with growth objectives. This operational improvement will increase efficiency and position INBS for sustained, long-term success in the global market.
Harry Simeonidis, President and CEO at INBS, commented, “This strategic realignment will refocus priorities to better serve our global markets, enhancing productivity and creating synergies across our teams. The new functional structure will streamline operations, optimizing our ability to deliver our innovative, non-invasive medical technologies across the globe.”
INBS’ first-of-its-kind solution uses fingerprint sweat to provide a quick, hygienic, and easy-to-use method for drug testing, delivering results in just minutes. This unique approach tests for common drugs of abuse, including cocaine, cannabis, methamphetamine, and opiates.
